Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 2Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Differentiated Thyroid Cancer 1

Interventions

selpercatinib 2pembrolizumab 2130-nm albumin-bound paclitaxel 2vandetanib 1trametinib 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1methyl N-acetylsibirosaminide 1lenvatinib 1fludarabine 1cemiplimab 1alectinib 1aldesleukin 1Thyrotropin Alfa 1Presenilin-1 1Panitumumab 1Interleukin-15 1Imatinib Mesylate 1IT-101 1IFL protocol 1Gemcitabine 1Dacarbazine 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Cetuximab 1Capecitabine 1Camptothecin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Neoplasms × Thyrotropin Alfa × Clear all
NCT03276988 2020-09-09

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

Genexine, Inc.

Phase 1/2 Completed
8 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡